Aserech Triangle Park, North Carolina - Saturday 1 مارس 2014 [ME NewsWire]
( BUSINESS WIRE ): The " Quintiles "to keep up with them for the World Day for rare diseases, which falls today, the existence of 350 million people worldwide suffer from rare diseases, and make up the meeting, the third largest country in the world in terms of population. In this context, shed light on the contribution of the company in the face of this challenge through a new set of studies and multimedia files "podcast" and video clips covering the latest developments and visions.
The disease is rarely the case affects less than 200 thousand dollars at any given time, according to the Food and Drug Administration 1. In Europe, the disease or the disease is considered rare if it affects less than 1 out of every 2,000 people 2. The doctor says Milena Canova, the first director of project management at the "Quintiles" in this context, "is to find patients for studies and one of the biggest challenges for these types of clinical trials in particular and rare diseases affect the numbers are relatively few people."
This involved "Quintiles" in more than 80 clinical trials on rare diseases, which include about 11 thousand patients in nearly 52 countries. Based on these experiences, the report issued today offers insights and aspirations about the design of clinical trials for diseases rare and the drug is on the market and the results of patient.
As part of its support for the deployment of these visions, explaining d. Canova in the file "podcast"
new approach adopted in clinical trials for diseases rare and how to adapt the model to suit any rare disease. These include the design of experiments approach to include surveillance based on data and ever-oriented sites and research plans for patients, specially designed for the field of rare diseases.
And contributes to global presence for "Quintiles", as well as clinical development, which results in the improvement of the patients reported. And was able to "Quintiles" By partnering with sponsors and research organizations, the development of many of the records for rare diseases, including hemophilia and cystic fibrosis and some rare species of cancer, for example.
Says Catherine Starzyk, winning a Masters degree in Science and Director of the Department of Epidemiology in the study of "Real World Lit Phys Research" (the study of the last stage in the real world) with "Quintiles": "allows us a level that go deeper in it within the market to conduct large studies long-term Relatively speaking, the goal of some of them lies in the registration information for each patient undergoing treatment for a specific product. "
In the context of new insights, discuss all of John Doyle, winner of the testimony doctoral and master's degrees in public health and who serves as senior vice president and managing director for consulting with "Quintiles", and Jeremy Brodas, Vice President of Business Solutions at "Quintiles", considerations of the development strategy 'Go to Market' including access to doctors, and access to the market, and medical education versus traditional sales activities.
Can be found on more than visions and aspirations for the development of drugs for rare diseases on the company's website .
About "Quintiles"
Company is "Quintiles" (included in the New York Stock Exchange under the symbol NYSE: Q) in the world's largest provider of development and commercialization of biopharmaceutical services. The company has a network of 28 thousand specialists working in more than 100 countries. We have helped to develop and commercialize all the drugs on the list of the 50 best medicine in the world in terms of sales. The company used "Quintiles" its comprehensive range of services in addition to its expertise therapeutic, scientific and analytical large-scale, to help customers run healthcare environment increasingly complex, while seeking to improve efficiency and effectiveness in the delivery of the best results in the field of health care. For more information about the company, "Quintiles", you can visit the following website: www.quintiles.com .
Please click here to subscribe to notifications of special mobile "Quintiles".
The text of the original language of this statement is the official version approved. The translator has provided assistance only and should consult the text of the original language, which is the only version with legal effect.
Contacts
"Quintiles"
Mary Mansfield
Media Relations
+ 1.919.998.2639
+1.919.259.3298
E-mail: Mansfield@quintiles.com
Carl Dionanan
Investor Relations
+1.919.998.2789
E-mail: InvestorRelations@quintiles.com
Permalink: http://www.me-newswire.net/ar/news/10188/ar
No comments:
Post a Comment